Harrow Inc., a prominent player in the health care sector, specifically within the pharmaceuticals industry, is headquartered in Nashville, Tennessee, United States. The company is renowned for its specialization in the discovery, development, and commercialization of ophthalmic pharmaceutical products. Harrow Inc. focuses on medications designed to treat a variety of eye conditions, including dry eye disease, glaucoma, allergies, infections, and other ophthalmic inflammatory conditions. For further details on their operations, interested parties can visit their official website at www.harrow.com .
As of the latest financial data, Harrow Inc. is listed on the Nasdaq stock exchange. The company’s market capitalization stands at approximately $1.73 billion USD. In terms of stock performance, Harrow Inc.’s closing price on January 12, 2026, was $47.19. This figure is situated near the 52-week high of $54.85, recorded on January 6, 2026. Conversely, the 52-week low was $20.85, observed on April 8, 2025.
Financial metrics reveal a price-to-earnings (P/E) ratio of -343.33, indicating that the company is currently experiencing negative earnings. Additionally, the price-to-book (P/B) ratio is 34.8515, suggesting that the company’s market valuation is at a premium relative to its book value. These financial indicators provide insight into Harrow Inc.’s valuation within the healthcare sector.
Despite its significant presence in the pharmaceuticals industry, Harrow Health (HROW) has not been featured in recent market news, with the latest public update dated January 4, 2026. The company’s most recent closing price was $47.84, which is close to the 52-week high. These financial and market details offer a comprehensive overview of Harrow Inc.’s current standing and performance in the market.
